Phase II trial of imatinib mesylate in patients with metastatic melanoma

Metastatic melanoma cells express a number of protein tyrosine kinases (PTKs) that are considered to be targets for imatinib. We conducted a phase II trial of imatinib in patients with metastatic melanoma expressing at least one of these PTKs. Twenty-one patients whose tumours expressed at least one...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, K B, Eton, O, Davis, D W, Frazier, M L, McConkey, D J, Diwan, A H, Papadopoulos, N E, Bedikian, A Y, Camacho, L H, Ross, M I, Cormier, J N, Gershenwald, J E, Lee, J E, Mansfield, P F, Billings, L A, Ng, C S, Charnsangavej, C, Bar-Eli, M, Johnson, M M, Murgo, A J, Prieto, V G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528157/
https://www.ncbi.nlm.nih.gov/pubmed/18728664
http://dx.doi.org/10.1038/sj.bjc.6604482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2528157/
https://www.ncbi.nlm.nih.gov/pubmed/18728664
http://dx.doi.org/10.1038/sj.bjc.6604482

Ejemplares similares